499 related articles for article (PubMed ID: 10192992)
1. [The Sézary syndrome].
Ferreira F; Correia TM; Callabro L; Andrade J
Acta Med Port; 1998 Dec; 11(12):1135-9. PubMed ID: 10192992
[TBL] [Abstract][Full Text] [Related]
2. Molecular staging of lymph nodes from 60 patients with mycosis fungoides and Sézary syndrome: correlation with histopathology and outcome suggests prognostic relevance in mycosis fungoides.
Fraser-Andrews EA; Mitchell T; Ferreira S; Seed PT; Russell-Jones R; Calonje E; Whittaker SJ
Br J Dermatol; 2006 Oct; 155(4):756-62. PubMed ID: 16965425
[TBL] [Abstract][Full Text] [Related]
3. Cytologic evaluation of lymphadenopathy associated with mycosis fungoides and Sezary syndrome: role of immunophenotypic and molecular ancillary studies.
Pai RK; Mullins FM; Kim YH; Kong CS
Cancer; 2008 Oct; 114(5):323-32. PubMed ID: 18798522
[TBL] [Abstract][Full Text] [Related]
4. Sézary syndrome in an 11-year-old girl.
Meister L; Duarte AM; Davis J; Perez JL; Schachner LA
J Am Acad Dermatol; 1993 Jan; 28(1):93-5. PubMed ID: 8425978
[TBL] [Abstract][Full Text] [Related]
5. [Sézary syndrome showing a stable clinical course for more than four years after oral administration of etoposide and methotrexate].
Hirayama Y; Nagai T; Ohta H; Koyama R; Matsunaga T; Sakamaki S; Niitsu Y
Rinsho Ketsueki; 2000 Sep; 41(9):750-4. PubMed ID: 11070938
[TBL] [Abstract][Full Text] [Related]
6. Sezary syndrome presenting with leonine facies and treated with low-dose subcutaneous alemtuzumab.
Oliveira A; Lobo I; Alves R; Lima M; Selores M
Dermatol Online J; 2011 Nov; 17(11):6. PubMed ID: 22136862
[TBL] [Abstract][Full Text] [Related]
7. Neurolymphomatosis associated with Sézary syndrome.
Bezier M; Reguiaï Z; Delaby P; Laroche L; Saïd G; Bernard P; Grange F
Arch Dermatol; 2009 Mar; 145(3):294-6. PubMed ID: 19289760
[TBL] [Abstract][Full Text] [Related]
8. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sézary syndrome from other cutaneous T-cell lymphomas.
Klemke CD; Fritzsching B; Franz B; Kleinmann EV; Oberle N; Poenitz N; Sykora J; Banham AH; Roncador G; Kuhn A; Goerdt S; Krammer PH; Suri-Payer E
Leukemia; 2006 Jun; 20(6):1123-9. PubMed ID: 16557241
[TBL] [Abstract][Full Text] [Related]
9. Oral bexarotene in a therapy-resistant Sézary syndrome patient: observations on Sézary cell compartmentalization.
el-Azhary RA; Bouwhuis SA
Int J Dermatol; 2005 Jan; 44(1):25-8. PubMed ID: 15663654
[TBL] [Abstract][Full Text] [Related]
10. Atopic dermatitis-like pre-Sézary syndrome: role of immunosuppression.
Sokołowska-Wojdyło M; Barańska-Rybak W; Cegielska A; Trzeciak M; Lugowska-Umer H; Gniadecki R
Acta Derm Venereol; 2011 Sep; 91(5):574-7. PubMed ID: 21681350
[TBL] [Abstract][Full Text] [Related]
11. Mycosis fungoides and the Sézary syndrome.
Kim YH; Hoppe RT
Semin Oncol; 1999 Jun; 26(3):276-89. PubMed ID: 10375085
[TBL] [Abstract][Full Text] [Related]
12. Fine-needle aspiration biopsy in the evaluation of lymphadenopathy associated with cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome).
Galindo LM; Garcia FU; Hanau CA; Lessin SR; Jhala N; Bigler RD; Vonderheid EC
Am J Clin Pathol; 2000 Jun; 113(6):865-71. PubMed ID: 10874888
[TBL] [Abstract][Full Text] [Related]
13. [Malignant lymphoma of the skin].
Nakajima H; Miyamoto H
Gan To Kagaku Ryoho; 1985 Sep; 12(9):1735-43. PubMed ID: 3876074
[TBL] [Abstract][Full Text] [Related]
14. [A woman with Sezary syndrome developed HTLV-1-associated myeloneuropathy. The reported case supports the theory of etiological connection].
Roupe G
Lakartidningen; 2003 Jul; 100(30-31):2441-2. PubMed ID: 12914139
[TBL] [Abstract][Full Text] [Related]
15. Sézary syndrome without erythroderma.
Henn A; Michel L; Fite C; Deschamps L; Ortonne N; Ingen-Housz-Oro S; Marinho E; Beylot-Barry M; Bagot M; Laroche L; Crickx B; Maubec E
J Am Acad Dermatol; 2015 Jun; 72(6):1003-9.e1. PubMed ID: 25981000
[TBL] [Abstract][Full Text] [Related]
16. T-cell receptor gamma gene rearrangement by multiplex polymerase chain reaction/heteroduplex analysis in patients with cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome) and benign inflammatory disease: correlation with clinical, histological and immunophenotypical findings.
Ponti R; Quaglino P; Novelli M; Fierro MT; Comessatti A; Peroni A; Bonello L; Bernengo MG
Br J Dermatol; 2005 Sep; 153(3):565-73. PubMed ID: 16120144
[TBL] [Abstract][Full Text] [Related]
17. Hydantoin-induced cutaneous pseudolymphoma with clinical, pathologic, and immunologic aspects of Sézary syndrome.
D'Incan M; Souteyrand P; Bignon YJ; Fonck Y; Roger H
Arch Dermatol; 1992 Oct; 128(10):1371-4. PubMed ID: 1417026
[TBL] [Abstract][Full Text] [Related]
18. Sustained remission of Sézary syndrome.
Bouwhuis SA; McEvoy MT; Davis MD
Eur J Dermatol; 2002; 12(3):287-90. PubMed ID: 11978575
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment of chemotherapy-refractory Sézary syndrome with alemtuzumab (Campath-1H).
Gautschi O; Blumenthal N; Streit M; Solenthaler M; Hunziker T; Zenhäusern R
Eur J Haematol; 2004 Jan; 72(1):61-3. PubMed ID: 14962265
[TBL] [Abstract][Full Text] [Related]
20. Utility of flow cytometry immunophenotyping and DNA ploidy studies for diagnosis and characterization of blood involvement in CD4+ Sézary's syndrome.
Lima M; Almeida J; dos Anjos Teixeira M; Queiros ML; Santos AH; Fonseca S; Balanzategui A; Justica B; Orfao A
Haematologica; 2003 Aug; 88(8):874-87. PubMed ID: 12935975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
